<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658020</url>
  </required_header>
  <id_info>
    <org_study_id>DW224-III-3</org_study_id>
    <nct_id>NCT01658020</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg</brief_title>
  <acronym>DW224-III-3</acronym>
  <official_title>Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chosun University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KangWon National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of Korea Saint Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masan Samsung Hospital, South Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Severance Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangneung Asan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple
      dose of Zabofloxacin Tablet 400 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, Multicenter, Double Blind, Active Controlled, Randomized Study to Evaluate the
      Efficacy and Safety of Zabofloxacin for Patients with acute bacterial exacerbation of
      Chronic obstructive pulmonary disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Cure Rate in the clinical populations</measure>
    <time_frame>10days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Primary Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure Rate in the clinical population</measure>
    <time_frame>36days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure Rate in the microbiological PP population</measure>
    <time_frame>10days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rate in the microbiological PP population</measure>
    <time_frame>10,36days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EXACT-PRO score for clinical populations</measure>
    <time_frame>10,36days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CAT scores for clinical populations</measure>
    <time_frame>10,36days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary Efficacy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>36days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety analysis is done to clinical ITT population and assessed by changes in numbers of results in Adverse Events monitoring, vital signs of populations laboratory examination.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>DW224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin Tablet 400mg given by oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Avelox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin Tablet 400mg given by oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin Tablet 400mg</intervention_name>
    <description>multiple-dose</description>
    <arm_group_label>Avelox</arm_group_label>
    <other_name>DW224</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Tablet 400mg</intervention_name>
    <description>multiple-dose</description>
    <arm_group_label>DW224</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female same or older than age of 40

          -  Severity of acute exacerbation of COPD must suit oral administration treatment

          -  Diagnosed as COPD before receiving written informed consent and outcome measure of
             spirometry testing confirmed as FEV1/FVC &lt; 0.7

          -  Subject showing following signs and symptoms:

             (i)Purulent Sputum or Sputum level is increased; (ii)Difficulty in breathing is
             increased

          -  Female subjects who might be pregnant must do pregnancy test and results should be
             negative before randomization is done. She must receive written informed consent form
             (NOTE: Subject who has used single hormone contraception for pregnancy control or has
             not been more than 1 year after Tubule ligation and menopause are excluded from the
             study)

          -  Subject who can agree and sign written informed consent form approved by IRB before
             participating in study and follow study requirements

        Exclusion Criteria:

          -  Subject who administered excess daily dose of antimicrobial/antibiotics in past 72
             hours before receiving written consent

          -  Diagnosed to have pneumonia by taking chest X-ray in past 48 hours before receiving
             written consent

          -  Diagnosed to have infectious diseases or such diseases results in complications
             before receiving written consent (NOTE: Septic shock, Bronchiectasis, Lung abscess,
             Pneumonia, Active tuberculosis, Pulmonary malignancy, Cystic fibrosis, Empyema,
             Asthma)

          -  Have kidney or liver diseases who correspond following criteria:

             (i) CCr &lt; 50 mL/min; (ii) BUN ≥ 30 mg/dl; (iii) ALT 또는 AST &gt; 3 x ULN; (iv) Total
             bilirubin &gt; 2 x ULN; (v) ALP &gt; 2 x ULN.

          -  Organic gastrointestinal disorder having abnormal absorption problem condition in
             past 6 months before receiving written consent (NOTE: Active Crohn's disease, active
             ulcerative colitis)

          -  Diagnosed to have neutropenia where absolute neutrophil count is &lt; 1,000cells/mm3
             (NOTE: Even though subject neutrophil count is &lt; 1,000cells/mm3, if it is acute
             infection, subject maybe possible to participate)

          -  Chronic Hepatitis B carrier

          -  Have proof that subject is Hepatitis C carrier or have Hepatitis C antibody

          -  Immunodeficiency diseases such as HIV positive, AIDS, Bone marrow transplant or
             leukemia

          -  Have medical history of hypersensitive reaction to antibiotics of fluoroquinolones

          -  Have medical history of seizure or administration of anti-seizure drug in past 1 year
             before receiving written consent (NOTE: Epilepsy, Convulsions, Myasthenia gravis)

          -  Medical history of ventricular arrhythmia

          -  Medical history of QTc prolongation or currently administering drug that delays QTc
             interval (NOTE: QTc prolongation means QTc interval &gt; 450 msec)

          -  Complex infections or diseases that can effect study assessment or need long-term
             antibiotic treatment exceeding 7 days

          -  Subject who has participated in Clinical trials or Bioequivalence test in past 30
             days before receiving written consent

          -  Clinically significant by observations considered as unsuitable based on medical
             judgement by investigators where current condition can effect quality of safety or
             data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yeon-Mok Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Do Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://medical.amc.seoul.kr/medservice/main/main.do</url>
    <description>Asan Medical Center</description>
  </link>
  <link>
    <url>http://www.dong-wha.co.kr/dw_main.asp</url>
    <description>Dong Wha Pharm. Co. Ltd.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute exacerbation of Chronic obstructive pulmonary disease</keyword>
  <keyword>Acute Exacerbation</keyword>
  <keyword>COPD</keyword>
  <keyword>Zabofloxacin</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Avelox</keyword>
  <keyword>DW224-III-3</keyword>
  <keyword>DW224</keyword>
  <keyword>DW224a</keyword>
  <keyword>DW224aa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
